Findings

What do systematic reviews say?

4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Systemic reactogenicity events

BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in systemic reactogenicity eventse compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.05 [0.86, 1.28]
3 studies · 27540 participants
Moderate

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Any adverse eventh

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 26924 participants
Low

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Serious adverse eventsk

BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.76 [0.54, 1.06]
1 study · 26924 participants
Low

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Local reactogenicity events

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 26924 participants
Low

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Local reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BBV152 – Bharat Biotech vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6289 participants
High

BBV152 – Bharat Biotech vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16973 participants
High

BBV152 – Bharat Biotech vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16976 participants
High

BBV152 – Bharat Biotech vs placebo

All‐cause mortalitye

BBV152 – Bharat Biotech showed no clear difference in all‐cause mortalitye compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.5 [0.17, 1.46]
1 study · 25753 participants
Low

BBV152 – Bharat Biotech vs placebo

Systemic reactogenicity events

BBV152 – Bharat Biotech leads to higher systemic reactogenicity eventsg compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.34 [1.15, 1.58]
2 studies · 25925 participants
High

BBV152 – Bharat Biotech vs placebo

Any adverse eventi

BBV152 – Bharat Biotech showed no clear difference in any adverse eventi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1 [0.94, 1.07]
1 study · 25753 participants
High

BBV152 – Bharat Biotech vs placebo

Serious adverse eventsi

BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.65 [0.43, 0.97]
1 study · 25928 participants
High

BBV152 – Bharat Biotech vs placebo

Local reactogenicity events

BBV152 – Bharat Biotech showed no clear difference in local reactogenicity eventsg compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.08 [0.95, 1.24]
2 studies · 25750 participants
High

NVX‐CoV2373 – Novavax vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NVX‐CoV2373 – Novavax vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 42175 participants
Moderate

mRNA‐1273 – ModernaTX vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 31632 participants
Moderate

NVX‐CoV2373 – Novavax vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25452 participants
Moderate

NVX‐CoV2373 – Novavax vs placebo

All‐cause mortalityh

NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.9 [0.3, 2.68]
1 study · 29582 participants
Low